Author(s):
Mohammad Intakhab Alam, Syam Mohan, Mohammad Ashafaq, Yosif Almoshari, Hafiz A. Makeen, Sohail Hussain
Email(s):
mialam@jazanu.edu.sa , smohan@jazanu.edu.sa , mashfaqisha@jazanu.edu.sa , yalmoshari@jazanu.edu.sa , hafiz@jazanu.edu.sa , shussainamu@gmail.com
DOI:
10.52711/0974-360X.2024.00764
Address:
Mohammad Intakhab Alam1, Syam Mohan2,3, Mohammad Ashafaq4, Yosif Almoshari1, Hafiz A. Makeen5, Sohail Hussain4*
1Department of Pharmaceutics, College of Pharmacy, Jazan University, Jazan, Saudi Arabia.
2Substance Abuse and Toxicology Research Centre, Jazan University, Jazan, Saudi Arabia.
3School of Health Sciences, University of Petroleum and Energy Studies, Dehradun, Uttarakhand, India.
4Department of Pharmacology and Toxicology, College of Pharmacy, Jazan University, Jazan, Saudi Arabia.
5Department of Clinical Pharmacy, College of Pharmacy, Jazan University, Jazan, Saudi Arabia.
*Corresponding Author,
Published In:
Volume - 17,
Issue - 10,
Year - 2024
ABSTRACT:
This research aims to investigate the feasibility of using nanostructured lipid carriers (NLC) loaded with Gefitinib to treat colorectal cancer by focusing on the inflammatory cytokine pathway, particularly on the JAK-STAT pathway. As part of the study, Gefitinib-loaded NLC (Nano-GEF) was prepared by homogenization method. Colorectal cancer cells HCT116 were subjected to a series of tests to determine cytotoxicity, including morphological assessment, MTT assay, DNA fragmentation analysis, evaluation of interleukin cytokines, and JAK-STAT pathway expression. According to the study's results, Nano-GEF has far stronger anti-cancer effects than the pure drug (GEF) against cells of colorectal cancer. Morphological studies and cytotoxicity assays confirm the selective action of Nano-GEF on cancer cells. Furthermore, the expression of pathways mediated by JAK-STAT provides further evidence of Nano-GEF's effectiveness as a potential anti-cancer therapy. By focusing on the inflammatory cytokine pathway (JAK-STAT), this research shows that gefitinib-loaded NLC might be a good technique to treat colorectal cancer. Based on the results, Nano-GEF has the potential to be an effective anti-cancer method that is more selective than the pure drug. These findings open the door to the creation of innovative pharmaceutical products as well as the possibility of applications in the assessment and treatment of cancer.
Cite this article:
Mohammad Intakhab Alam, Syam Mohan, Mohammad Ashafaq, Yosif Almoshari, Hafiz A. Makeen, Sohail Hussain. Determining the anticancer effect of Gefitinib-loaded NLCs through investigating the inflammatory cytokine (JAK-STAT) pathway. Research Journal of Pharmacy and Technology. 2024; 17(10):4968-4. doi: 10.52711/0974-360X.2024.00764
Cite(Electronic):
Mohammad Intakhab Alam, Syam Mohan, Mohammad Ashafaq, Yosif Almoshari, Hafiz A. Makeen, Sohail Hussain. Determining the anticancer effect of Gefitinib-loaded NLCs through investigating the inflammatory cytokine (JAK-STAT) pathway. Research Journal of Pharmacy and Technology. 2024; 17(10):4968-4. doi: 10.52711/0974-360X.2024.00764 Available on: https://rjptonline.org/AbstractView.aspx?PID=2024-17-10-49
REFERENCE:
1. Sen A, Kumar K, Khan S, Pathak P, Singh A. Current Therapy in Cancer: Advances, Challenges, and Future Directions. Asian Journal of Nursing Education and Research. 2024; 14(1): 77-4. doi: 10.52711/2349-2996.2024.00016
2. Yadav AR, Mohite SK. Cancer- A Silent Killer: An Overview. Asian Journal of Pharmaceutical Research. 2020; Sep 16; 10(3): 213-216. doi: 10.5958/2231-5691.2020.00036.2
3. Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Przegladgastroenterologiczny. 2019; Jan 6; 14(2): 89-103. doi: 10.5114/pg.2018.81072
4. Sachdeo RA, Charde MS, Chakole RD. Colorectal Cancer: An Overview. Asian Journal of Research in Pharmaceutical Sciences. 2020; Sept 16; 10(3): 211-223. doi: 10.5958/2231-5659.2020.00040.5
5. Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Translational Oncology. 2021; Oct 1; 14(10): 101174. doi: 10.1016/j.tranon.2021.101174.
6. Loree JM, Kopetz S. Recent developments in the treatment of metastatic colorectal cancer. Therapeutic advances in medical oncology. 2017; 9(8): 551-564. 10.1177/1758834017714997
7. Siegel RL, Miller KD, Jemal A. Colorectal Cancer Mortality Rates in Adults Aged 20 to 54 Years in the United States, 1970-2014. JAMA. 2017; Aug 8; 318(6): 72–574. 10.1001/jama.2017.7630
8. Chanda C. Role of Inflammatory Cytokines during Lung Cancer Progression: A Review. Research Journal of Pharmacy and Technology. 2018; Jan 30; 11(11): 5163-5165 doi: 10.5958/0974-360X.2018.00943.5
9. Dhairyasheel G, Adhikrao Y, Varsha G. Design and Development of Solid Self-Microemulsifying Drug Delivery of Gefitinib. Asian Journal of Pharmaceutical Technology. 2018; Dec 25; 8 (4): 193-199. doi: 10.5958/2231-5713.2018.00031.4
10. Chang TC, Chin YT, Nana AW, Wang SH, Liao YM, Chen YR, et al. Enhancement by nanodiamino-tetrac of antiproliferative action of gefitinib on colorectal cancer cells: mediation by EGFR sialylation and PI3K activation. Hormones and Cancer. 2018; Dec 1; 9: 420–32. 10.1007/s12672-018-0341-x
11. Huang CW, Chen YT, Tsai HL, Yeh YS, Su WC, Ma CJ, et al. EGFR expression in patients with stage III colorectal cancer after adjuvant chemotherapy and on cancer cell function. Oncotarget. 2017; Dec 9; 8: 114663. 10.18632/oncotarget.23072
12. Gelibter AJ, Gamucci T, Pollera CF, Di Costanzo F, Nuzzo C, Gabriele A et al. A phase II trial of gefitinib in combination with capecitabine and oxaliplatin as first-line chemotherapy in patients with advanced colorectal cancer. Current Medical Research and Opinion. 2007; Sep 1; 23: 2117–23. 10.1185/030079907X226113
13. Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine kinase inhibitors-a review on pharmacology, metabolism and side effects. Current Drug Metabolism. 2009; Jun 1; 10: 470–81. 10.2174/138920009788897975
14. Bornare AS, Saudagar RB. Nanostructured Lipid Carrier (NLC): A Modern Approach for Transdermal Drug Delivery. Research Journal of Pharmacy and Technology. 2017; Mar 26; 10(8): 2784-2792. doi: 10.5958/0974-360X.2017.00493.0
15. Sangar OS, Patil AC, Payghan SA. Nanoparticles: As a Nano based Drug Delivery System. Asian Journal of Research in Pharmaceutical Sciences. 2022; 12(1): 11-6. doi: 10.52711/2231-5659.2022.00003
16. Khandbahale SV. A Review- Nanosuspension Technology in Drug Delivery System. Asian Journal of Pharmaceutical Research. 2019; Jul 3; 9(2): 130-138. doi: 10.5958/2231-5691.2019.00021.2
17. Sadique MA, Yadav S, Ranjan P, Verma S, Salammal ST, Khan MA, et al. High-performance antiviral nano-systems as a shield to inhibit viral infections: sARS-CoV-2 as a model case study. Journal of materials chemistry B. 2021; Jun 16; 9: 4620–4642. 10.1039/d1tb00472g
18. Sharma PK, Ruotolo A, Khan R, Mishra YK, Kumar KNK, Kim NY, Kaushik AK. Perspectives on 2D-borophene flatland for smart bio-sensing. Materials Letter. 2022; Feb 1; 308: 131089. 10.1016/j.matlet.2021.131089
19. Khandbahale SV, Saudagar RB. Nanoparticle- A Review . Asian Journal of Research in Pharmaceutical Sciences. 2017; Oct 17; 7(3): 162-172. doi: 10.5958/2231-5659.2017.00026.1
20. Vignesh BE, Tamil SA. Nanopharmacology: A Novel Approach in Therapeutics. Asian Journal of Research in Pharmaceutical Sciences. 2019; March 16; 9(1): 09-16. doi: 10.5958/2231-5659.2019.00003.1
21. Makeen HA, Mohan S, Al-Kasim MA, Attafi IM, Ahmed RA, Syed NK, Set al. Gefitinib loaded nanostructured lipid carriers: characterization, evaluation and anti-human colon cancer activity in vitro. Drug delivery. 2020; Dec 1; 27(1): 622–631. 10.1080/10717544.2020.1754526
22. Moongkarndi P, Kosem N, Kaslungka S, Luanratana O, Pongpan N, Neungton N. Antiproliferation, antioxidation and induction of apoptosis by Garcinia mangostana (mangosteen) on SKBR3 human breast cancer cell line. Journal of Ethnopharmacology. 2004; Jan 1; 90(1): 161–166. 10.1016/j.jep.2003.09.048
23. Hayon T, Dvilansky A, Sphilberg O, Nathan I. Appraisal of the MTT-based Assay as a Useful Tool for Predicting Drug Chemosensitivity in Leukemia. Leukemia and Lymphoma. 2003; Nov 1; 44(11): 1957–1962. 10.1080/1042819031000116607
24. Hussain S, Ashafaq M, Alshahrani S, Bokar IAM, Siddiqui R, Alam MI, et al. Hepatoprotective Effect of Curcumin Nano-Lipid Carrier against Cypermethrin Toxicity by Countering the Oxidative, Inflammatory, and Apoptotic Changes in Wistar Rats. Molecules. 2023; Jan 16; 28: 881. 10.3390/molecules28020881
25. Hussain S, Jali AM, Alshahrani S, Khairat KHM, Siddiqui R, Alam MI, et al. Hepatoprotective and Antioxidant Effects of Nanopiperine against Cypermethrin via Mitigation of Oxidative Stress, Inflammations and Gene Expression Using qRT-PCR. International Journal of Molecular Sciences. 2023; Oct 19; 24: 15361. 10.3390/ijms242015361
26. Ashafaq M, Hussain S, Alshahrani S, Siddiqui R, Alam MI, Elhassan TMM, et al. Neuroprotective Effects of Nano-Curcumin against Cypermethrin Associated Oxidative Stress and Up-Regulation of Apoptotic and Inflammatory Gene Expression in Rat Brains. Antioxidants. 2023; Mar 4; 12: 644. 10.3390/antiox12030644
27. Sagar TM, Porter DW, Robinson VA, Lindsley WG, Schwegler-berry DE, Castranova V. Improved method to disperse nanoparticles for in vitro and in vivo investigation of toxicity. Nanotoxicology. 2007; Jan 1; 1: 118-29. https://doi.org/10.1080/17435390701381596
28. Zhao G, Zhu G, Huang Y, Zheng W, Hua J, Yang S, Zhuang J, Ye J. IL-6 mediates the signal pathway of JAK-STAT3-VEGF-C promoting growth, invasion and lymph angiogenesis in gastric cancer. Oncology Reports. 2016; Mar 1; 35(3): 1787-95. 10.3892/or.2016.4544
29. Lou YF, Zou ZZ, Chen PJ, Huang GB, Li B, Zheng DQ, Yu XR, Luo XY. Combination of gefitinib and DNA methylation inhibitor decitabine exerts synergistic anti-cancer activity in colon cancer cells. PLoS One. 2014; Mar 29; 9(5): 97719. 10.1371/journal.pone.0097719
30. Umbreit C, Erben P, Faber A, Hofheinz RD, Aderhold C, Weiss C, Hoermann K, Wenzel A, Schultz JD. MMP9, Cyclin D1 and β-Catenin are useful markers of p16-positive squamous cell carcinoma in therapeutic EGFR inhibition in vitro. Anticancer Research. 2015; Jul 1; 35: 3801-10.
31. Segovia-Mendoza M, Díaz L, González-González ME, Martínez-Reza I, García-Quiroz J, Prado-Garcia H, Ibarra-Sánchez MJ, Esparza-López J, Larrea F, García-Becerra R. Calcitriol and its analogues enhance the antiproliferative activity of gefitinib in breast cancer cells. The Journal of Steroid biochemistry and Molecular Biology. 2015; Apr 1; 148: 122-131. 10.1016/j.jsbmb.2014.12.006
32. Ni J, Zhang L. Evaluation of three small molecular drugs for targeted therapy to treat non-small cell lung cancer. Chinese Medical Journal. 2016; Feb 5; 129: 332-340. 10.4103/0366-6999.174484
33. Heinrich PC, Behrmann I, Mueller-Newen G, Shaper F, Graeve L. Interleukin 6-type cytokine signaling through the gp130 ⁄ jak ⁄ stat pathways. The Biochemical Journal. 1998; Sep 1; 334: 297–314. 10.1042/BST20130267
34. Kurihara N, Bertolini D, Suda T, Akiyama Y, Roodman D. IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. Journal of Immunology. 1990; Jun 1; 144: 4226–4230. 10.4049/jimmunol.144.11.4226
35. Hacovirta H, Syed B, Jegou B, Parvinen M. Function of interleukin-6 as an ihibitor of meiotic DNA synthesis in the rat seminiferous epithelium. Molecular and Cellular Endocrinology. 1995; Feb 27; 108: 193–198. 10.1016/0303-7207(95)03475-m
36. Smith PC, Keller ET. Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice. The Prostate. 2001; Jun 15; 48: 47–53. 10.1002/pros.1080
37. Bollrath J, Phesse TJ, Von-Burstin VA, Putoczki T, Bennecke M, Bateman T, et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell. 2009; Feb 3; 15(2): 91-102. 10.1016/j.ccr.2009.01.002
38. Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and the development of colitis-associated cancer. Cancer Cell. 2009; Feb 3; 15(2): 103–113. 10.1016/j.ccr.2009.01.001
39. Balkwill F. Tumor necrosis factor and cancer. Nature Reviews Cancer. 2009; May1; 9(5): 361–371. 10.1038/nrc2628
40. Marelli G, Sica A, Vannucci L, Allavena P. Inflammation as target in cancer therapy. Current Opinion in Pharmacology. 2017; Aug 1; 35: 57–65. 10.1016/j.coph.2017.05.007
41. Yao X, Huang J, Zhong H, Shen N, Faggioni R, Fung M, et al. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacology and Therapeutics. 2014; Feb 1; 141(2): 125–139. 10.1016/j.pharmthera.2013.09.004
42. West NR, McCuaig S, Franchini F, Powrie F. Emerging cytokine networks in colorectal cancer. Nature Reviews Immunology. 2015; Oct 1; 15(10): 615–629. 10.1038/nri3896
43. Miranda DO, Anatriello E, Azevedo LR, Cordeiro JFC, Peria FM, Floria-Santos M. et al. Elevated serum levels of proinflammatory cytokines potentially correlate with depression and anxiety in colorectal cancer patients in different stages of the antitumor therapy. Cytokine. 2018; Apr 1; 104: 72–77. 10.1016/j.cyto.2017.09.030
44. Wu CW, Wang SR, Chao MF, Wu TC, Lui WY, P'Eng FK, et al. Serum interleukin-6 levels reflect disease status of gastric cancer. The American Journal of Gastroenterology. 1996; Jul 1; 91(7): 1417–1422.
45. Lin MT, Juan CY, Chang KJ, Chen WJ, Kuo ML. IL-6 inhibits apoptosis and retains oxidative DNA lesions in human gastric cancer AGS cells through up-regulation of anti-apoptotic gene mcl-1. Carcinogenesis. 2001; Dec 1; 22: 1947–1953. 10.1093/carcin/22.12.1947
46. Oltvai ZM, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates programmed cell death. Cell. 1993; Aug 27; 74: 609–619. 10.1016/0092-8674(93)90509-o
47. Nathan B, Gusterson B, Jadayel D. et al. Expression of BCL-2 in primary breast cancer and its correlation with tumor phenotype. For the International (Ludwig) Breast Cancer Study Group. Annals of Oncology. 1994; May; 5: 409–414. 10.1093/oxfordjournals.annonc.a058871
48. Wyllie AH. Apoptosis and the regulation of cell numbers in normal and neoplastic tissues: an overview. Cancer Metastasis Reviews. 1992; Sep 1; 11: 95–103. 10.1007/BF00048057